VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2
about
Control of the immune response by pro-angiogenic factorsImproved nucleosome-positioning algorithm iNPS for accurate nucleosome positioning from sequencing data.Prothymosin α and a prothymosin α-derived peptide enhance T(H)1-type immune responses against defined HER-2/neu epitopes.VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors.Cancer prevention and therapy through the modulation of the tumor microenvironment.Relationship of VEGF/VEGFR with immune and cancer cells: staggering or forward?Prognostic factors in patients with advanced renal cell carcinoma treated with VEGF-targeted agents.Tumor-like microenvironment in oral lichen planus: evidence of malignant transformation?Endothelial epsins as regulators and potential therapeutic targets of tumor angiogenesis.The Sabotaging Role of Myeloid Cells in Anti-Angiogenic Therapy: Coordination of Angiogenesis and Immune Suppression by Hypoxia.Cross-reactive antibodies enhance live attenuated virus infection for increased immunogenicity.Immune effects of bevacizumab: killing two birds with one stoneThe role and significance of VEGFR2+ regulatory T cells in tumor immunityTargeted attack: mechanisms by which ovarian cancers suppress the immune system.VEGF Potentiates GD3-Mediated Immunosuppression by Human Ovarian Cancer Cells.Immune cells regulate VEGF signalling via release of VEGF and antagonistic soluble VEGF receptor-1.Ex Vivo Induced Regulatory Human/Murine Mesenchymal Stem Cells as Immune Modulators.Targeting VEGF/VEGFR to Modulate Antitumor Immunity.[Impact of VEGF-A in exhaustion of intratumoral T cells].Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.Methylseleninic Acid Sensitizes Ovarian Cancer Cells to T-Cell Mediated Killing by Decreasing PDL1 and VEGF Levels
P2860
Q27004733-0C168857-076D-4EBB-8030-CEEFA0B6DDE1Q30853426-105F9025-9F28-400D-BE95-976896AEFC2FQ34993170-E25BE492-ED8F-422D-827B-70544ED07C07Q35064894-A54F2BEE-EA7C-4547-8A44-E65BF1E1C029Q37058267-C960B0CC-CCFA-4F7F-ADF0-EA2926CFAEAFQ37094060-E34B6B2C-F8D0-48D3-A447-BA720E911529Q38196855-018FF751-EC0F-492C-857C-736368C9171FQ38685090-736ADFD4-D79E-477E-8472-6A0DF4D0B236Q38939975-B9BA4FFD-ED58-47A0-B403-3FC8E1852B36Q39034031-D7A1BA29-F0EF-4622-8E67-33BEC26A05FBQ40088326-193A1A81-59D5-49A6-924C-D2FCA97FDC2DQ41401879-B7561601-9971-4255-9EA2-D522D0E621CDQ41499942-6B59046A-8A41-4BEE-806E-2309CD3D138DQ41723681-9127BB14-49BB-4028-8920-8E9A1DE9224CQ41738853-C7D2A084-F652-4F6D-B1FA-6348708F44ECQ48128395-D198CB3B-594B-4E5F-BD5D-D75E37F39E05Q53554451-1CF53204-3A8F-4D1F-A476-8069BB620588Q55008337-498DCF27-660C-470F-87DF-7F0C43E67FA2Q55056908-4C1D22A1-418C-4B8A-A1A5-85B2FD526589Q55190117-FC9E2BF1-60B8-48FE-BF47-48AEE5F0CFF3Q57490205-E575326C-806F-4B99-A682-EE6BA49DBF49
P2860
VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
VEGF directly suppresses activ ...... ancer via VEGF receptor type 2
@ast
VEGF directly suppresses activ ...... ancer via VEGF receptor type 2
@en
type
label
VEGF directly suppresses activ ...... ancer via VEGF receptor type 2
@ast
VEGF directly suppresses activ ...... ancer via VEGF receptor type 2
@en
prefLabel
VEGF directly suppresses activ ...... ancer via VEGF receptor type 2
@ast
VEGF directly suppresses activ ...... ancer via VEGF receptor type 2
@en
P2093
P2860
P356
P1476
VEGF directly suppresses activ ...... ancer via VEGF receptor type 2
@en
P2093
A Antsaklis
A C Ziogas
A Rodolakis
D Haidopoulos
P2860
P2888
P304
P356
10.1038/BJC.2012.468
P407
P577
2012-11-01T00:00:00Z